Medtronic PLC vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Medtronic PLC trades at $90.61 (market cap $116.07B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51. The key difference: Medtronic PLC pays a 3.18% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Medtronic PLC is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| MDT | VNQI | |
|---|---|---|
Market Cap | $116.07B | — |
Sector | Health | — |
52-Week High | $105.35 | $50.76 |
52-Week Low | $73.75 | $43.26 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.72, up 0.35% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S. with a competitive expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent institutional activity shows Balefire LLC reduced its position by 78.7% in Q2 2026.
The fund offers international real estate diversification benefits but faces currency risk and potential underperformance versus U.S. REITs. Current technical momentum supports near-term upside, though investors should weigh the trade-off between higher yield and historical total return lag against domestic alternatives.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →